{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["52(1)"],"submitter":["Bugarski-Kirola D"],"funding":["Acadia Pharmaceuticals Inc"],"pubmed_abstract":["<h4>Background and hypotheses</h4>Negative symptoms of schizophrenia (NSS) carry a substantial burden, and there are no treatments currently approved for NSS. The efficacy of pimavanserin, a selective 5-HT2A inverse agonist and antagonist, in treating NSS was assessed.<h4>Study design</h4>ADVANCE-2 was a phase 3, randomized, double-blind, placebo-controlled study of pimavanserin in patients with schizophrenia and predominantly negative symptoms. Patients were randomized (1:1) to receive pimavanserin (34 mg/day) or placebo alongside ongoing background antipsychotic medication. Eligible adults were aged 18-55 years and had access to a caregiver. The primary and key secondary endpoints were the change from baseline to week 26 in the Negative Symptom Assessment-16 (NSA-16) total score and Clin"],"journal":["Schizophrenia bulletin"],"pagination":["sbaf034"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12809779"],"repository":["biostudies-literature"],"pubmed_title":["A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative Symptoms."],"pmcid":["PMC12809779"],"pubmed_authors":["Liu IY","Marder SR","Bugarski-Kirola D","Arango C"],"additional_accession":[]},"is_claimable":false,"name":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative Symptoms.","description":"<h4>Background and hypotheses</h4>Negative symptoms of schizophrenia (NSS) carry a substantial burden, and there are no treatments currently approved for NSS. The efficacy of pimavanserin, a selective 5-HT2A inverse agonist and antagonist, in treating NSS was assessed.<h4>Study design</h4>ADVANCE-2 was a phase 3, randomized, double-blind, placebo-controlled study of pimavanserin in patients with schizophrenia and predominantly negative symptoms. Patients were randomized (1:1) to receive pimavanserin (34 mg/day) or placebo alongside ongoing background antipsychotic medication. Eligible adults were aged 18-55 years and had access to a caregiver. The primary and key secondary endpoints were the change from baseline to week 26 in the Negative Symptom Assessment-16 (NSA-16) total score and Clin","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-06T15:59:33.906Z","creation":"2026-06-02T03:10:54.034Z"},"accession":"S-EPMC12809779","cross_references":{"pubmed":["40181715"],"doi":["10.1093/schbul/sbaf034"]}}